VERICIGUAT - Generic Drug Details

What are the generic drug sources for vericiguat and what is the scope of patent protection?

Vericiguat is the generic ingredient in one branded drug marketed by MSD and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vericiguat has two hundred and fourteen patent family members in fifty countries.

One supplier is listed for this compound.

Summary for VERICIGUAT

International Patents:	214
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	29
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VERICIGUAT
What excipients (inactive ingredients) are in VERICIGUAT?	VERICIGUAT excipients list
DailyMed Link:	VERICIGUAT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VERICIGUAT

Constraining patent/regulatory exclusivity:

9,604,948

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VERICIGUAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	PHASE2
Ottawa Heart Institute Research Corporation	PHASE2
Heart and Stroke Foundation of Canada	PHASE2

See all VERICIGUAT clinical trials

Pharmacology for VERICIGUAT

Drug Class	Soluble Guanylate Cyclase Stimulator
Mechanism of Action	Guanylate Cyclase Stimulators

Anatomical Therapeutic Chemical (ATC) Classes for VERICIGUAT

C01DX	Other vasodilators used in cardiac diseases
C01D	VASODILATORS USED IN CARDIAC DISEASES
C01	CARDIAC THERAPY
C	Cardiovascular system

Paragraph IV (Patent) Challenges for VERICIGUAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VERQUVO	Tablets	vericiguat	5 mg and 10 mg	214377	4	2025-01-21

US Patents and Regulatory Information for VERICIGUAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes	9,604,948		Y	Y
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No	8,921,377
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No	9,993,476

EU/EMA Drug Approvals for VERICIGUAT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Verquvo	vericiguat	EMEA/H/C/005319Treatment of symptomatic chronic heart failure	Authorised	no	no	no	2021-07-16

International Patents for VERICIGUAT

Country	Patent Number	Title	Estimated Expiration
Singapore	185460
South Korea	20130116001	THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSC)
Philippines	12015501494	METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIMIDINES
Spain	2567795

Supplementary Protection Certificates for VERICIGUAT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2576547	SPC/GB21/058	United Kingdom		PRODUCT NAME: VERICIGUAT AND ITS SALTS, SOLVATES AND SOLVATES OF THE SALTS; REGISTERED: UK PLGB 00010/0748 20210719; UK PLGB 00010/0749 20210719; UK PLGB 00010/0750 20210719; UK FURTHER MA ON IPSUM 20210719
2576547	CR 2021 00032	Denmark		PRODUCT NAME: VERICIGUAT OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE; REG. NO/DATE: EU/1/21/1561 20210720
2576547	PA2021518	Lithuania		PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716
2576547	30/2021	Austria		PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 (MITTEILUNG) 20210720

VERICIGUAT Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Vericiguat?

Vericiguat, developed by Bayer and marketed as part of the Hemopexin family, targets chronic heart failure (CHF) with reduced ejection fraction. It was approved by the FDA in January 2021 for this indication. The drug's focus is on improving outcomes in a segment with high unmet needs, especially among patients intolerant to existing therapies like ACE inhibitors or beta-blockers.

Market Overview

The global heart failure drugs market was valued at approximately $10 billion in 2022, with expectations to reach $15 billion by 2030, growing at a CAGR of about 4.3% (source: MarketsandMarkets). Vericiguat's segment targets a subset within this market: patients with high-risk CHF with reduced ejection fraction who are inadequately managed with current treatments.

Competitive Landscape

Key competitors include:

• Entresto (sacubitril/valsartan) by Novartis
• Coreg (carvedilol) by Roche
• Inspra (eplerenone) by Pfizer

Vericiguat differentiates itself by targeting the soluble guanylate cyclase pathway, potentially offering benefits in patients who do not respond optimally to standard treatments.

Adoption Drivers

• Evidence from the VICTORIA trial demonstrated a 10% relative risk reduction in cardiovascular death or hospitalization for heart failure.
• Clinical guidelines increasingly recognize vericiguat as a treatment option for high-risk CHF patients.
• Ongoing trials explore its efficacy in broader heart failure populations, potentially expanding its indications.

Market Challenges

• Competition from well-established drugs with broader approvals.
• Price pressures, especially in markets with cost-sensitive healthcare systems.
• Need for clinician education on the drug's niche benefits.

Regulatory and Policy Factors

• Approved in the United States, Europe, and Japan, with regulatory pathways facilitated by positive trial data.
• Reimbursement policies vary, with higher coverage likelihood in markets emphasizing evidence-based practice for high-risk patients.

What Is the Financial Trajectory for Vericiguat?

Sales Performance

Vericiguat’s initial launch target was limited to high-risk, HFrEF patients, estimating peak sales of approximately $2 billion globally by 2025 (source: EvaluatePharma). Early sales in 2022, after the FDA approval, totaled around $100 million, with forecasts indicating rapid growth as prescriber adoption increases.

Revenue Drivers

• Market penetration in the U.S. and Europe.
• Expansion into additional indications, such as heart failure with preserved ejection fraction (HFpEF), pending trial results.
• Competitive pricing strategies to secure formulary placement and payer coverage.

Cost Structure and Profitability

• Bayer's R&D investment in vericiguat approximated $300 million through clinical development and regulatory processes.
• Manufacturing costs are estimated at 20-25% of sales, consistent with biologics and complex small molecules.
• Margins are likely to improve as scale increases and generic competition remains minimal in the short term.

Long-Term Outlook

• With high unmet needs, vericiguat has potential for sustained growth if clinical outcomes validate broader use.
• The company plans to invest in post-marketing surveillance and real-world evidence generation to support formulary access and expanded indications.

Risks and Barriers

• Market share capture faces resistance from established therapies.
• Delays or failures in ongoing trials, such as in HFpEF, could limit expansion.
• Competitive innovations or new drug approvals could diminish vericiguat’s market position.

What Are the Key Takeaways?

Vericiguat operates in a high-growth segment for heart failure drugs, targeting an unmet patient subset. Its market penetration depends on clinical acceptance, formulary positioning, and competitive dynamics. Early revenue growth aligns with expectations, but long-term success hinges on evidence supporting broader indications and integration into clinical practice.

What Are Some Frequently Asked Questions?

1. How does vericiguat differ from existing heart failure treatments?

Vericiguat targets the soluble guanylate cyclase pathway, offering a novel mechanism compared to ACE inhibitors, beta-blockers, and ARBs. It is indicated for high-risk patients who remain symptomatic despite standard therapy, providing an additional therapeutic option.

2. What are the primary barriers to vericiguat's market expansion?

Barriers include competition from established drugs, clinician familiarity, pricing pressures, and the need for further evidence to broaden its indications.

3. What is the current international regulatory status?

Vericiguat has received approval in the U.S., European Union, and Japan. Regulatory processes in other regions remain under review or pending.

4. How significant is the opportunity in heart failure with preserved ejection fraction (HFpEF)?

Potentially significant if ongoing trials demonstrate efficacy, which would open a much larger market segment. Currently, vericiguat’s approval is limited to HFrEF high-risk patients.

5. What are the prospects for generic competition?

As a relatively new chemical entity, vericiguat has patent protection until at least 2030, with no immediate generic equivalents. Patent challenges could alter this trajectory.

References

1. MarketsandMarkets. (2022). Heart Failure Drugs Market report.
2. EvaluatePharma. (2023). Pharmaceutical Sales Forecasts.
3. Bayer AG. (2021). Vericiguat FDA Approval Press Release.
4. VICTORIA Trial Publication. (2021). The New England Journal of Medicine.
5. FDA. (2021). Vericiguat approval documentation.